Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 dose-finding study in adults with moderate to severe atopic dermatitis
2023-505414-15-00Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing GSK1070806 dose arm(s) with Placebo (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index to Week 16. Started Mar 2024; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-505414-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505414-15-00.